Bruton's Tyrosine Kinase Inhibitors: Recent Updates.
Int J Mol Sci
; 25(4)2024 Feb 12.
Article
de En
| MEDLINE
| ID: mdl-38396884
ABSTRACT
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts. Similarly, the BTK receptor is involved in signaling pathways such as chemokine receptor signaling, Toll-like receptor signaling, and Fc receptor signaling. Due to their unique mechanism, these agents provide a diverse utility in a variety of disease states not limited to the field of malignant hematology and are generally well-tolerated.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs hématologiques
/
Tumeurs
Limites:
Humans
Langue:
En
Journal:
Int J Mol Sci
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique